Compare HHH & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HHH | CRNX |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | United States | United States |
| Employees | 500 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.9B |
| IPO Year | 2023 | 2018 |
| Metric | HHH | CRNX |
|---|---|---|
| Price | $61.38 | $35.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $90.00 | $74.78 |
| AVG Volume (30 Days) | 543.2K | ★ 903.6K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.21 | N/A |
| Revenue | ★ $1,474,892,000.00 | $1,039,000.00 |
| Revenue This Year | $14.04 | $722.66 |
| Revenue Next Year | N/A | $183.79 |
| P/E Ratio | $28.05 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $61.41 | $24.10 |
| 52 Week High | $91.07 | $57.99 |
| Indicator | HHH | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 24.66 | 26.12 |
| Support Level | N/A | $33.23 |
| Resistance Level | $71.26 | $37.23 |
| Average True Range (ATR) | 1.68 | 1.50 |
| MACD | -0.31 | -0.01 |
| Stochastic Oscillator | 0.11 | 3.41 |
Howard Hughes Holdings Inc, through its subsidiary, operates a large-scale, mixed-use real estate platform focused on the development of master planned communities (MPCs), the investment in strategic real estate development opportunities, and the ownership and operation of income-producing properties. The group operates through three reportable business segments: Operating Assets, MPCs, and Strategic Developments. Maximum revenue is generated from the MPC segment, which consists of the development and sale of land in large-scale, long-term community development projects in and around Las Vegas, Nevada; Houston, Texas; and Phoenix, Arizona. Revenues are mainly generated through the sale of residential and commercial land to homebuilders and developers.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.